The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.